Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials

Authors Cooper C, Anzueto A, Decramer M, Celli B, Tashkin D, Leimer, Kesten

Published 9 May 2011 Volume 2011:6 Pages 269—275

DOI https://doi.org/10.2147/COPD.S17864

Review by Single-blind

Peer reviewer comments 3

Christopher B Cooper1, Antonio Anzueto2, Marc Decramer3, Bartolome Celli4, Donald P Tashkin1, Inge Leimer5, Steven Kesten6
1David Geffen School of Medicine, University of California, Los Angeles, CA; 2University of Texas Health Science Center, South Texas Veterans Health Care System, San Antonio, TX; 3University of Leuven, Leuven, Belgium; 4Women's and Brigham Hospital, Boston, MA; 5Boehringer Ingelheim International GmbH, Ingelheim, Germany; 6Uptake Medical Corp, Tustin, CA, USA

Background: Data have highlighted the potential bias introduced by withdrawal of inhaled corticosteroids at randomization in chronic obstructive pulmonary disease trials examining inhaled corticosteroids. Analyses were conducted to determine whether this was true of inhaled anticholinergic withdrawal in tiotropium trials.
Methods: A pooled analysis of randomized, double-blind, placebo-controlled, parallel-group tiotropium trials of at least six months' duration was performed. Trials had similar inclusion and exclusion criteria. Exacerbation definition was standardized. Patients were divided into two groups, ie, D (anticholinergics discontinued at randomization, previously prescribed) and ND (anticholinergics not discontinued, not previously prescribed).
Results: Demographics were balanced between the D (n = 5846) and ND (n = 6317) groups, except for higher cumulative smoking (56 pack-years versus 48 pack-years), lower forced expiratory volume in one second (FEV1)/forced vital capacity (43% versus 48%), and lower baseline FEV1 (35.8% predicted versus 42.4% predicted) in the D group. In both groups, tiot ,ropium reduced the risk for an exacerbation (hazard ratio [HR] = 0.83, P < 0.0001 [D] versus 0.79, P < 0.0001 [ND]) and a hospitalized exacerbation (HR = 0.85, P = 0.0467 versus 0.79, P = 0.0094). Tiotropium reduced the number of exacerbations per patient-year (rate ratio [RR] = 0.82, P < 0.0001 [D] versus RR = 0.80, P < 0.0001 [ND]) and associated hospitalizations per patient-year (RR = 0.88, P = 0.015 [D] versus RR = 0.74, P < 0.0001 [ND]).
Conclusion: Tiotropium reduced exacerbations in patients who did and did not have anticholinergics discontinued upon randomization in clinical trials.

Keywords: chronic obstructive pulmonary disease, clinical trials, exacerbations, inhaled anticholinergics, tiotropium

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]